...
首页> 外文期刊>Journal of vascular surgery >A model of in vivo human venous thrombosis that confirms changes in the release of specific soluble cell adhesion molecules in experimental venous thrombogenesis.
【24h】

A model of in vivo human venous thrombosis that confirms changes in the release of specific soluble cell adhesion molecules in experimental venous thrombogenesis.

机译:一种体内人静脉血栓形成模型,该模型确认了实验性静脉血栓形成过程中特定可溶性细胞粘附分子释放的变化。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: The mechanisms of venous thrombogenesis have been studied by using animal models and cells in culture. The results from these systems may not, however, be relevant to the human condition. The aim of this study was to develop a method by which thrombus could be safely produced in a human vein in vivo. The model that was developed was used as a means of studying the changes in soluble adhesion molecule expression in human venous thrombogenesis. METHODS: An autologous thrombin extract was used to generate experimental thrombi in the disconnected portion of the long saphenous veins of 30 patients who were undergoing routine bilateral varicose vein surgery. The contralateral vein was perfused with thrombin extract diluent buffer to act as the control. The concentration of soluble P-, E- and L-selectin, intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule-1 were measured by means of specific enzyme-linked immunosorbent assays in samples of blood taken from veins in which thrombus had formed and in contralateral control veins. RESULTS: Thrombosis invariably formed when at least 100 IU of thrombin activity was administered. Thrombus formation was independent of the time that the thrombin extract was allowed to remain within the emptied vessel. Thrombosis never developed in control vessels that were similarly treated with the buffer used to dilute the thrombin extract. Experimental thrombi were composed mainly of red cells, with layers of fibrin next to platelet and leukocyte packages. These findings are similar to those observed in samples of established human venous thrombi. There were small but significantly higher levels of the adhesion molecules, soluble P-selectin, and vascular cell adhesion molecule-1 in blood taken from veins in which experimental thrombi had formed, compared with controls (P =.015 and.007, respectively; Wilcoxon signed rank test). Serum levels of soluble L-selectin, E-selectin, and ICAM-1 were not affected by thrombosis. CONCLUSION: This model is safe and reproducible. It produces thrombi with a morphology similar to that described for established human deep venous thrombi. The model may be appropriate for the study of the early changes that occur during human venous thrombogenesis and may also be of value in testing the efficacy of novel antithrombotic agents.
机译:目的:已经通过使用动物模型和培养细胞研究了静脉血栓形成的机制。但是,这些系统的结果可能与人体状况无关。这项研究的目的是开发一种可以在人体内静脉内安全地产生血栓的方法。开发的模型被用作研究人类静脉血栓形成中可溶性粘附分子表达变化的手段。方法:使用自体凝血酶提取物在30例接受常规双侧静脉曲张手术的患者的长隐静脉的不连续部分中产生实验性血栓。对侧静脉灌注凝血酶提取物稀释液缓冲液作为对照。通过特异性酶联免疫吸附法测定了从静脉中抽取的血液样本中的可溶性P-,E-和L-选择素,细胞间粘附分子1(ICAM-1)和血管细胞粘附分子-1的浓度。形成血栓并在对侧控制静脉内。结果:当给予至少100 IU凝血酶活性时,血栓形成总是发生。血栓形成与凝血酶提取物留在倒空血管内的时间无关。在用稀释凝血酶提取物的缓冲液同样处理过的对照血管中,血栓从未形成。实验性血栓主要由红细胞组成,在血小板和白细胞包装旁有一层纤维蛋白。这些发现与在已建立的人静脉血栓样本中观察到的相似。与对照组相比,血液中形成实验性血栓的血液中的黏附分子,可溶性P-选择素和血管细胞黏附分子-1含量较低,但明显高于对照组(分别为P = .015和.007; Wilcoxon签署等级测试)。可溶性L-选择素,E-选择素和ICAM-1的血清水平不受血栓形成的影响。结论:该模型是安全且可重复的。它产生的血栓的形态与已建立的人深静脉血栓的形态相似。该模型可能适用于研究人类静脉血栓形成过程中发生的早期变化,也可能在测试新型抗血栓形成剂的功效中具有价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号